CCR5 and malignant colon neoplasm: Furthermore, CCR5 inhibition by Maraviroc (MVC), an allosteric and reversible inhibitor, is considered a therapeutic strategy used in clinical trials for the treatment of metastatic breast and colon cancer [13, 15].